EARLY TREATMENT: USE THE BEST FIRST Early treatment with pharmacological approach Focus on COPD Stage II Pierluigi Paggiaro Cardio-Thoracic and Vascular.

Slides:



Advertisements
Similar presentations
Definition of COPD COPD is a preventable and treatable disease with some significant extrapulmonary effects that may contribute to the severity in individual.
Advertisements

GOLD MANAGEMENT PLAN FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
BY DR.Khaled Helmy Chest Specialist Al Mahmora Chest Hospital Ministry of Health - Egypt COPD SCOPE ON.
Optimizing the Management of Chronic Obstructive Pulmonary Disease (COPD) Note to the Speaker: All bold underlined statements must be read aloud to the.
The burden of COPD Exacerbations.
PREVENTING COPD EXACERBATIONS
Current strategies for COPD treatement Jaideep A. Gogtay MD Cipla Ltd, Mumbai, India.
Grazie per aver scelto di utilizzare a scopo didattico questo materiale delle Guidelines 2011 libra. Le ricordiamo che questo materiale è di proprietà.
OBESITY AND ASTHMA Dr. Enrico Heffler MD, Specialist in Allergy and Clinical Immunology Allergy and Clinical Immunology - University.
ICS in COPD – A Risk Factor for CAP? Rate of pneumonia in ICS Studies
Grazie per aver scelto di utilizzare a scopo didattico questo materiale delle Guidelines 2011 libra. Le ricordiamo che questo materiale è di proprietà.
Professor of Respiratory Medicine
GOLD Clasification Antonio Anzueto MD Professor Medicine University of Texas.
CHRONIC OBSTRUCTIVE PULMONARY DISEASE Treatment Opportunities in a Heartsink Disease Jim Reid.
Dr Patrick Mallia MD PhD NIHR Clinical Lecturer
Reversibility: Redefining Airflow Obstruction in COPD /09 ©AstraZeneca LP. All rights reserved.
Dr. Danny Galdermans Dept Respiratory Medicine ZNA Middelheim Antwerp
Applied Epidemiology Epidemiology of Chronic Obstructive Pulmonary Disease (COPD) By Chris Callan 23 April 2008.
05/12/04 Lung Health StudySlide 1 of 6 Lung Health Study Heavy Smokers Experienced a Greater Benefit in the Reduction of the Decline Rate of their Pulmonary.
Asthma What is Asthma ? V1.0 1997 Merck & ..
Lung function decline and physical activity
Definition of COPD COPD is a preventable and treatable disease with some significant extrapulmonary effects that may contribute to the severity in individual.
Definition of COPD COPD is defined by GOLD (2014 update) as:*
22/06/2011.  Asthma – an introduction (Vanessa)  Diagnosis and management of chronic asthma in line with current BTS guidelines (Dr Lowery)  3 x Case.
Chronic Obstructive Pulmonary Disease and Asthma: All That Wheezes? Clifford Courville, MD Pulmonary, Allergy, and Critical Care.
Inhaled corticosteroids in preschool asthmatic children
A STHMA - HOW TO CHOOSE AND INTERPRET LUNG FUNCTION TESTS - A VIEW OF REFERRING PHYSICIAN Matjaž Fležar MD PhD.
© 2013 Global Initiative for Chronic Obstructive Lung Disease
“How your approach in COPD might change in 2012”
End stage Lung Disease: What is it and what are some treatment options? NC Cardiopulmonary Rehabilitation Association Meeting March 14, 2014;
SGA 2003-W SS Slide 1 Capacity of Oral SINGULAIR to Prevent Asthma Exacerbations CApacidad de SIngulair ™ Oral en la Prevencion de Exacerbaciones.
Asma na Infância Renato T. Stein, M.D. Pontifícia Universidade Católica Porto Alegre, Brazil.
Definition COPD def- A disease state characterized by air flow limitation that is not fully reversible It is expected to be the 3 rd leading cause of.
GOLD Update 2011 Rabab A. El Wahsh, MD. Lecturer of Chest Diseases and Tuberculosis Minoufiya University REVISED 2011.
1 COPD Phenotypes Stephen I Rennard University of Nebraska Florianopolis, Brazil October 2009.
Component 1: Measures of Assessment and Monitoring n Two aspects: –Initial assessment and diagnosis of asthma –Periodic assessment and monitoring.
Real life COPD patients compared to large COPD study populations An UNLOCK external validity study A.L. Kruis, LUMC, Leiden, the Netherlands B. Stallberg,
Community based integrated intervention for prevention and management of Chronic Obstructive Pulmonary Disease in Guangdong, China: cluster randomised.
Ali …. 65 years old C/O exercise intolerance for 2 years.
COPD Diagnosis & Management Anil Ramineni Specialist Respiratory Physiotherapist Community Respiratory Team.
LSU Journal Club Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD WISDOM study H. Magnussen MD, et al. Nisha Loganantharaj, PGY1 April 21,
COPD? Where Are We Headed?
Prescribing for patients with COPD Evidence Update Emma Blanden- Pharmacist.
Analysis of chronic obstructive pulomnary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK):
Definition Chronic obstructive pulmonary disease (COPD) is characterized by chronic airflow limitation and a range of pathological changes in the lung.
Management of stable chronic obstructive pulmonary disease (2) Seminar Training Primary Care Asthma + COPD D.Anan Esmail.
CHEST 2014; 145(4): 호흡기내과 R3 박세정. Cigarette smoking ㅡ the most important risk factor for COPD in the US. low value of FEV 1 : an independent predictor.
RESPONSE TO ADD-ON INHALED CORTICOSTEROIDS IN COPD BASED ON AIRWAY HYPERRESPONSIVENESS TO MANNITOL Andreas Scherr, MD ; Salome Schafroth Török, MD ; Anja.
Chronic Obstructive Pulmonary Disease(COPD)
COPD – Primary Care Update
Research where it is most needed National Respiratory Strategy
Dr. Kevin Gruffydd-Jones Box Surgery, Wiltshire, England
Miguel Angel Martı´nez-Garcı´a, MD; Juan-Jose Soler-Catalun˜ a, MD;
Asthma-COPD Overlap Syndrome (ACOS) Challenges Diagnosing ACOS
Blood eosinophils as a biomarker in alpha 1 antitrypsin deficiency
Blood eosinophil count and exacerbation risk in patients with COPD
Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease that is characterized by persistent respiratory symptoms and.
Highlights From the Inaugural COPD7USA Conference: Focus on Treatment Challenges in COPD.
Prof Dr Guy JOOS Dept Respiratory Medicine Ghent University Hospital
Il ruolo dell’infiammazione nella BPCO
Personalizing COPD Therapy According to Recent Clinical Trial Evidence
Ruolo delle riacutizzazioni della BPCO
Roflumilast negli studi di Fase III: i dati di efficacia
Gestione clinica della BPCO
Fenotipizzazione della BPCO
Roflumilast: il programma di sviluppo clinico
Identificazione del sottogruppo di pazienti responsivi
Roflumilast in aggiunta ai corticosteroidi inalatori
Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification based on symptom and risk evaluation. a) GOLD model of symptom/risk evaluation.
D94- COPD: EPIDEMIOLOGY AND THERAPY
Presentation transcript:

EARLY TREATMENT: USE THE BEST FIRST Early treatment with pharmacological approach Focus on COPD Stage II Pierluigi Paggiaro Cardio-Thoracic and Vascular Department, University of Pisa, Italy Annual Meeting ACCP – Capitolo Italiano Honolulu, Hawaii, 23 oct 2011

Main characteristics of COPD Non completely reversible airway obstruction Variable combination of chronic bronchitis and emphysema Progressive decline in FEV1 Progressive deterioration in – dyspnoea – exercise limitation Relevant role of exacerbations – in progression of the disease – in quality of life

The natural history of FEV1 decline in COPD patients Fletcher and Peto, BMJ 1977

Recent long-term trial have confirmed the progressive decline in FEV1 in untreated moderate-severe COPD Miravitlles et al, IJCOPD 2009

Long-term longitudinal studies have only partially confirmed the rate of FEV1 decline at different baseline FEV1 Decramer and Cooper, Thorax 2010

GOLD stage II has a greater FEV1 decline than GOLD stage III and GOLD stage IV Decramer and Cooper, Thorax 2010

Is it possible to modify the natural history of COPD ? Several interventional studies –Lung Health Study I (ipratropium bromide) –ICS treatment Euroscope (budesonide) Copenhagen City Heart Study (budesonide) LHS II (triamcinolone) ISOLDE(fluticasone) –UPLIFT study (tiotropium) –TORCH study (Salm/Fluti) Negative results in the primary outcome

Long-term smoking cessation may modify the FEV1 decline Scanlon et al, AJRCCM 2000

Short and long-term studies with inhaled corticosteroids (ICS) Effective in reducing number and/or severity of exacerbations –Several studies, with different but consistent results (Paggiaro et al, Lancet 1997) Effect associated with: –Improvement in FEV1 –Improvement in quality of life –In subjects with FEV1 < 50% and frequent exacerbations Studies over 3-4 years, with the aim to modify natural history of the disease –All studies negative on improving the progressive decline of FEV1 (Euroscop, ISOLDE, LHS-II, CCLS) –Confirmation of the positive effect on exacerbations and other secondary outcomes

Soriano, Chest 2007 No effect of regular use ICS on FEV1 decline in COPD patients

In the Uplift study, tiotropium induces an important improvement in FEV 1 which persists over 4 years * Day 30 (steady state) * * * * * * * * Month * * * * * * * * * Post-Bronch FEV 1  = 47 – 65 mL Pre-Bronch FEV 1  = 87 – 103 mL (n=2516) (n=2374) (n=2494) (n=2363) *P< vs. control. Repeated measure ANOVA was used to estimate means. Means are adjusted for baseline measurements. Baseline trough FEV 1 (observed mean) = (trough), (peak). Patients with ≥3 acceptable PFTs after day 30 were included in the analysis.

Sub-analysis of the UPLIFT study Different response to tiotropium, according to: –Gender: male vs female Tashkin et al, Respir Med 2010 – Smoking habit: current vs ex vs intermittent Tashkin et al, ERJ 2010 –GOLD II stage ** Decramer et al, Lancet 2009 –Acute reversibility; reversible vs non reversible Hanania et al, Resp Res 2011 –No additional therapies (ICS/LABA) ** Troosters et al, ERJ 2010 –Age: lower than 50 yrs vs higher than 50 yrs ** Morice et al, Respir Med 2010

Reversible and non reversible COPD patients had similar results from tiotropium addition Hanania et al, Resp Res 2011

In moderate COPD, tiotropium significantly reduces the decline in post-bronc FEV1 Decramer et al, Lancet 2009

Celli et al, AJRCCM 2008 Post-hoc analysis of TORCH study Salm/Fluti decreases the decline in FEV1

Rationale for early treatment in COPD Symptoms and limitation in daily life –Present also in mild airway obstruction and/or hyperinflation Decline in FEV1 –Greater in early phases –Positive effect of treatment easier to be observed Airway and lung inflammation / exacerbations –Present in the early stages –More steroid-sensitive in early stage (?) Need to identify “rapid decliners”

May early treatment effectively prevent progressive deterioration in COPD ? Decramer et al, Respir Med 2011

Factors contributing to the progression of COPD Persistence of smoking habit Pulmonary function –FEV1 –IC Exercise capacity –6MWT, physical activity Nutritional status –BMI, FFM Rate of exacerbations

COPD exacerbations represent an important outcome, among the PROs –COPD patients may have exacerbations, which increase in number and severity with the increase in the severity of the pathology of the disease –The impact of exacerbations increases over time, leading to: Greater decline in pulmonary function 1 Increase in symptoms 2 Deterioration in health status 3 Increased risk of hospitalization 4 –Severe exacerbations increase the risk of mortality 4,5 1. Donaldson GC et al. Thorax 2002; 57: ; 2. Donaldson GC et al. Eur Respir J 2003; 22: ; 3. Seemungal TA et al. Am J Respir Crit Care Med 1998; 157: ; 4. Groenewegen KH et al. Chest 2003; 124: ; 5. Soler-Cataluna JJ et al. Thorax 2005; 60:

Donaldson et al, Thorax 2002 Frequent exacerbations are related to a greater decline in FEV1

High frequency of exacerbations increases the risk of mortality in COPD Soler-Cataluna JJ et al. Thorax 2005 ≥ 3 riacutizzazioni/anno 0 0,2 0,4 0,6 0,8 1,0 Probabilità di sopravvivenza 50 0 riacutizzazioni/anno1–2 riacutizzazioni/anno Tempo (mesi) p<0,0002 p=0,069 p<0,0001

ECLIPSE: 3-year longitudinal observational study Vestbo et al. ERJ COPD patients, GOLD II-IV 336 ‘healthy’ smokers 246 non smokers baseline3 Months 6 M12 M18 M24 M36 M30 M V1V2V3V4V5V6V7V8

Frequent exacerbators are represented in all GOLD stages Hurst et al, NEJM 2010

Frequent exacerbators represent a specific constant phenotype

Alsaeedi et al, Am J Med 2002 Inhaled corticosteroids reduce the risk of exacerbations in COPD

Moderate-severe exacerbation in 3 yrs *p < vs placebo; † p = vs SALM; ‡ p = vs FP Mean number of exacerbation/year * 0.93 * 0.85 * †‡ 25% reduction PlaceboSALMFPSALM/FP Trattamenti Calverly et al, NEJM 2007

Salm/Fluti reduces all causes of mortality of COPD in comparison with placebo Calverly et al, NEJM 2007

“Asthma” pattern in COPD Sputum eosinophilia During acute exacerbations –In up to 50% of AE –Mainly in virus-induced AE In stable COPD –In 30% about of patients –Associated with exhaled NO, acute reversibility (?) –Non associated with age, smoke, atopy, etc Different response to inhaled or oral CS

Virus-induced exacerbations of COPD are associated with greater sputum eosinophilia Papi et al, AJRCCM 2006

Sputum eosinophilia in stable COPD Observed in up to 30-40% of patients Lower than in asthma Not related to other clinical features –Chronic bronchitis ? –Acute reversibility ? How to select these patients ?

High frequency of sputum eosinophils in COPD patients

Papi et al, AJRCCM 2000 COPD patients with partial airway reversibility have higher levels of exhaled NO

Brightling et al, Thorax 2005 Sputum eosinophilia predicts a better response to CS in COPD patients

A strategy aiming to minimize sputum eosinophilia reduces the number of severe exacerbations of COPD Siva et al, ERJ 2007

Airway inflammation is present in COPD, also in earlier stages Hogg et al, NEJM 2004

Malondealdehayde (MDA), a marker of oxidative stress in EBC, is increased in stable moderate COPD patients Bartoli et al, Med Inflamm 2011

Conclusions Progression of COPD is more evident in early phase –In GOLD I-II stages Exacerbations represent a major target of treatment –Efficacy of ICS and ICS/LABA –Also in earlier stages Early treatment –Better chance of modifying natural history Phenotyping of COPD –“asthmatic” feature  role of ICS

A more flexible approach, based on symptoms and exacerbations, and not only on FEV1, has been now considered in the future GOLD guidelines